CordIn is under clinical development by Gamida Cell and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CordIn’s likelihood of approval (LoA) and phase transition for Aplastic Anemia took place on 19 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
In addition, the same event on 19 Jul 2022 decreased CordIn’s LoA and PTSR for Myelodysplastic Syndrome.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CordIn Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CordIn is under development for the treatment of hemoglobinopathies including aplastic anemia and hypo-plastic myelodysplastic syndrome. It is administered as an intravenous infusion. The therapeutic candidate is CD133+ cells derived from allogenic umbilical cord blood cells. The drug candidate is developed based on NAM platform technology. It was under development for sickle cell disease and beta thalassaemia.
Gamida Cell overview
Gamida Cell (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia; GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.
Quick View CordIn LOA Data
|Highest Development Stage|